Nsg Mouse Model
Nsg Mouse Model - Related Videos
07:10
Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
0 Views •
Cited by 13 •
2019
This protocol provides a method to establish humanized mice (hu-NSG) via intrahepatic injection of human hematopoietic stem cells into radiation-conditioned neonatal NSG mice. The hu-NSG mouse is susceptible to HIV infection and combinatorial antiretroviral therapy (cART) and serves as a suitable pathophysiological model for HIV replication and latency investigations.
03:16
Patient-derived Xenograft Modeling: A Technique to Generate Melanoma Mouse Models
0 Views •
2023
In this video, human-derived melanoma cells are implanted subcutaneously into the flank region of an immunocompromised mouse. The PDX model allows preclinical investigation of melanoma cells that better recapitulate the tumor heterogeneity and melanoma aggressiveness observed in in vivo conditions.
06:24
Mouse Models of Periventricular Leukomalacia
0 Views •
Cited by 28 •
2010
We established mouse models of periventricular leukomalacia (PVL), the predominant brain injury in premature infants characterized by periventricular white matter lesions. Hypoxia/ischemia with/without systemic infection are the primary causes of PVL. Unilateral carotid ligation and hypoxia exposure with/without lipopolysaccharide injection creates PVL-like lesions in P6 mice.
07:37
Mouse Models for Graft Arteriosclerosis
0 Views •
Cited by 17 •
2013
We describe protocols for our mouse graft arteriosclerois (GA) models which involve interposition of a mouse vessel segment into a recipient of the same inbred strain. By backcrossing additional genetic changes into the vessel donor, the model can assess the effect of specific genes on GA.
09:01
Chronic Salmonella Infected Mouse Model
0 Views •
Cited by 12 •
2010
Establish a chronic bacterial infected mouse model with persistent Salmonella typhimurium colonization in intestine for 27 weeks.
FAQs
The model’s immune defect arises from two layers of genetic alteration. The NOD background is combined with Prkdc and Il2rg mutations; together, these changes prevent functional T- and B-cell development and severely impair natural killer cell activity. This reduced host immune activity creates the biological setting needed for human tumor cells or patient-derived xenografts to engraft in vivo.
Impaired natural killer cell activity complements the loss of functional T and B cells in limiting the mouse’s ability to mount effective immune responses. This combination makes the host more permissive for maintaining implanted human cancer material. Consequently, researchers can examine tumor behavior in vivo without the introduced cells being eliminated by the full range of normal mouse immune defenses.
Using an NSG mouse model lets investigators examine several cancer outcomes in a living organism rather than studying tumor cells only in isolation. The same experimental setting can support analysis of tumor growth, metastatic behavior, treatment response, and interactions between cancer cells and the human immune system. These outcomes help connect cellular observations with whole-organism biological effects.
A typical study begins by establishing human tumor material in the mice, either as human tumor cells or as a patient-derived xenograft. After engraftment, researchers can follow tumor growth or metastasis and assess biological responses to an intervention. This sequence links model establishment with measurable disease behavior and treatment-related outcomes in vivo.
NSG mice are particularly useful when a study requires preclinical testing of cancer treatments in a living system. Researchers can use the model to evaluate targeted therapies, immunotherapies, or approaches intended for personalized cancer treatment, then examine treatment response as a biological outcome. Its value is therefore not limited to measuring whether a tumor forms.
Patient-derived xenografts provide a route for examining patient-origin tumor material within the NSG setting. This supports personalized treatment research by allowing investigators to study how such material behaves in vivo and responds to candidate therapies. The model consequently helps relate tumor-specific biology to preclinical treatment evaluation while retaining the context of a living organism.